आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
इस रिपोर्ट का अभी अनुवाद नहीं हुआ है। अनुवाद कतार पकड़ने पर कुछ मिनट में रिफ़्रेश करें।
StockMarketAgent Research · Analyzed 2026-10-04
Our latest published analysis: CNC rated Reduce
Centene Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
The base scenario represents the modal operating path with a target of $51.46 and an assigned probability of 55.0%, implying an expected return of -18.3% relative to $62.99. In this scenario, Centene successfully stabilizes its core Medicaid business as post-redetermination member attrition concludes and state actuarial rate adjustments gradually align with medical cost trends. Commercial Marketplace operations deliver pretax margins within the guided range, supported by positive risk-adjustment transfers. Overhead streamlining initiatives lower administrative expense ratios, supporting normalized operating margins and driving diluted earnings per share toward consensus expectations over the forecast horizon. Investors would confirm this path through consecutive quarters of stable medical loss ratios and realized administrative cost efficiencies.
Consolidated operating margins normalize gradually toward historical industry benchmarks
Medicaid expansion population stabilizes within guided portfolio proportions
Marketplace pretax margins achieve guided ranges supported by risk-adjustment positioning
Selective debt retirement and capital discipline preserve balance sheet liquidity
Bull20%
Price target
$59.33
-5.8% from spot
The bull scenario outlines an accelerated recovery path toward Potential value of $59.33, reflecting a target of $59.33 and a probability of 20.0%, delivering a potential return of -5.8% from $62.99. This outcome requires state Medicaid rate increases to exceed medical inflation, fully restoring underwriting profitability across the core portfolio. Concurrently, favorable risk-adjustment determinations lift Commercial Marketplace margins beyond guided expectations, while enterprise overhead streamlining generates structural administrative cost reductions above initial targets. Robust cash conversion accelerates debt paydown, de-risking upcoming maturities and prompting market multiple expansion toward leading managed care peers. Disconfirmation would occur if state rate updates fail to exceed trend or exchange competition erodes pricing power.
Sensitivity: Ke × terminal growth
The highlighted cell is Fair value when every assumption sits at its base level ($51.46). Each row and column shows what Fair value becomes when one assumption moves.
Ke ↓ / g →
2.0%
2.3%
2.5%
2.8%
3.0%
8.4%
$53.3
$53.3
$53.3
$53.3
$53.3
8.9%
$52.2
$52.2
$52.2
$52.2
$52.2
9.4%
$51.5
$51.5
$51.5
$51.5
$51.5
9.9%
$50.2
$50.2
$50.2
$50.2
$50.2
10.4%
$49.3
$49.3
$49.3
$49.3
$49.3
Scorecard
Published factor rows and weighted composite
Calendar
Next earnings
Upcoming earnings date and setup when available.
Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector percentile context
Refreshed 2026-10-28 19:55 UTC
Forward P/E11.2
P25 n/aP50 n/aP75 n/a
Trailing P/E0
P25 n/aP50 n/aP75 n/a
ROE6.7
P25 n/aP50 n/aP75 n/a
ROIC6.9
P25 n/aP50 n/aP75 n/a
Benchmarks · 1M
All CNC indicators
Market & fundamental data
Available fields
252
Groups with data
10
Currency
USD
Showing 252 of 252 available metrics for this ticker.
Profile and market data
Ticker identity, listing, currency, market cap, and source dates.
41
Metric
Value
Amount currency
USD
CIK code
0001071739
Company name
Centene Corporation
Country
United States
Country code
US
CUSIP number
15135B101
Earnings date
2026-10-27
Earnings time
bmo
Employees
61,100
Employees change
600
Employees growth
0.99%
Enterprise value
$28.1B
Exchange
NYSE
Financial currency
USD
Financial report date
2026-09-30
First seen
2026-05-09
Fiscal year end
December
Founded
1984
In index
SP500
Industry
Healthcare Plans
IPO date
2001-12-13
Is primary listing
Yes
Is SPAC
No
ISIN number
US15135B1017
Last 10-K release date
2026-02-17
Last earnings date
2026-10-27
Last refreshed
2026-10-28
Last stock split date
2019-02-07
Last stock split type
Forward
Market cap
$33.2B
Market cap category
Large-Cap
Next earnings date
2027-02-05
Options
Yes
Price
$67.14
Price currency
USD
Sector
Healthcare
SIC code
6324
Stock price date
2026-10-28
Symbol
CNC
U.S. state
Missouri
Website
https://www.centene.com
Valuation
Multiples, yields, enterprise-value ratios, and valuation checks.
33
Metric
Value
Adjusted P/E ratio
12.74x
Average P/E ratio (10Y)
22.33x
Average P/E ratio (3Y)
13.45x
Average P/E ratio (5Y)
19.74x
Earnings yield
4.4%
EV/Earnings
19.26x
EV/EBIT
8.12x
EV/EBITDA
5.99x
EV/FCF
7.13x
EV/Sales
0.16x
FCF / EV yield
14.02%
FCF yield
11.85%
Forward EV/Sales
0.15x
Forward P/E
13.06x
Forward P/S
0.17x
Graham number
54.58341
Graham upside
-18.81%
Industry forward P/E
15.03x
Industry P/E
21.44x
Lynch fair value
$43.33
Lynch upside
-35.55%
P/(FCF - SBC) ratio
8.98x
P/(OCF - SBC) ratio
7.42x
P/B ratio
1.53x
P/E ratio
22.75x
P/FCF ratio
8.44x
P/OCF ratio
7.05x
P/S ratio
0.18x
PEG ratio
0.35x
Price / tangible book value
4.54x
Price/EBITDA ratio
7.09x
Sector forward P/E
23.56x
Sector P/E
50.13x
Profitability
Margins, returns on capital, cash conversion, and quality metrics.
19
Metric
Value
EBIT margin
1.92%
EBITDA margin
2.6%
Effective tax rate
23.91%
FCF margin
2.19%
Gross margin
11.34%
Operating margin
1.92%
Pretax margin
1.06%
Profit margin
0.81%
Profit per employee
$23,895
Revenue per employee
$3M
ROA
2.68%
ROA (5Y)
3.1%
ROCE
8.61%
ROE
6.74%
ROE (5Y)
0.87%
ROIC
6.88%
ROIC (5Y)
6.33%
SBC / revenue
0.13%
Tax / revenue
0.25%
Growth
Revenue, earnings, cash-flow, and forward growth indicators.
24
Metric
Value
EPS growth 10Y
8.04%
EPS growth 3Y
-12.66%
EPS growth 5Y
18.76%
EPS growth quarters
3
EPS growth years
0
FCF growth
17.49%
FCF growth 3Y
-10.23%
FCF growth 5Y
-6.92%
Net income growth 3Y
-15.78%
Net income growth 5Y
14.68%
Net income growth quarters
3
Net income growth years
0
OCF growth
16.24%
OCF growth 10Y
26.23%
OCF growth 3Y
-8.96%
OCF growth 5Y
-6.22%
Revenue growth
7.6%
Revenue growth (Q)
0.2%
Revenue growth (QoQ)
1.37%
Revenue growth 10Y
18.57%
Revenue growth 3Y
8.99%
Revenue growth 5Y
9.59%
Revenue growth quarters
83
Revenue growth years
27
Financial statements
Income-statement and cash-flow amounts, totals and per share.
18
Metric
Value
Capital expenditures
$-781M
EBIT
$3.5B
EBITDA
$4.7B
EPS
$2.95
FCF per share
$7.96
Financing cash flow
$-2.1B
Free cash flow
$3.9B
Free cash flow minus SBC
$3.7B
Gross profit
$20.5B
Income taxes
$459M
Investing cash flow
$1.3B
Net borrowing
$-2.1B
Net cash flow
$3.7B
Net income
$1.5B
Operating cash flow minus SBC
$4.5B
Operating income
$3.5B
Revenue
$180.4B
Stock-based compensation
$236M
Financial strength
Debt, cash, solvency, accounting-quality, and balance-sheet signals.
21
Metric
Value
Book value per share
$44.87
Debt / EBITDA
3.24
Debt / equity
0.7
Debt / FCF
3.94
Goodwill
$10.8B
Interest coverage
5.46
Net cash (debt)
$5.2B
Net cash / market cap
15.5%
Net debt / EBITDA
-1.1
Net debt / equity
-0.23
Net debt / FCF
-1.31
Piotroski F-Score
7
Property, plant and equipment
$2.1B
Shareholders' equity
$22.3B
Tangible book value
$7.3B
Tangible book value per share
$14.81
Total assets
$79.3B
Total cash
$23.6B
Total debt
$15.5B
Total liabilities
$57B
WACC
8.12%
Liquidity
Current-asset coverage and working-capital efficiency metrics.
5
Metric
Value
Asset turnover
2.24
Current ratio
1.16
Net working capital
$-14.2B
Quick ratio
1.12
Working capital
$6.4B
Dividends and buybacks
Dividend yield, payout, buybacks, and shareholder-yield indicators.
3
Metric
Value
Buyback yield / dilution
-0.16%
Dividend yield
0%
Shareholder yield
-0.16%
Performance and technicals
Returns, volatility, beta, momentum, RSI, and moving-average context.
78
Metric
Value
10Y price change
110.36%
10Y return CAGR
7.72%
10Y total return
110.36%
150-day SMA
$59.81
15Y price change
666.9%
15Y return CAGR
14.55%
15Y total return
666.95%
1D price change
-2.28%
1M price change
7.9%
1M total return
7.9%
1W price change
-5.8%
1W total return
-5.8%
1Y price change
101.22%
1Y return CAGR
101.32%
1Y total return
101.22%
20-day SMA
$67.40
200-day SMA
$55.12
20Y price change
969.33%
20Y return CAGR
12.58%
20Y total return
969.42%
3M price change
4.1%
3M total return
4.1%
3Y price change
-1.15%
3Y return CAGR
-0.38%
3Y total return
-1.15%
50-day SMA
$65.94
50-day SMA vs 200-day SMA
50over200
52-week high
$72.50
52-week high date
2026-10-22
52-week low
$31.63
52-week low date
2026-03-30
5Y price change
-5.45%
5Y return CAGR
-1.11%
5Y total return
-5.45%
6M price change
53.35%
6M total return
53.35%
All-time high
$98.53
All-time high date
2022-08-15
All-time low
$1.19
All-time low date
2001-12-13
Average true range (ATR)
$2.61
Average volume
4.5M
Beta (1Y)
1.13
Beta (2Y)
0.33
Beta (5Y)
1.13
Change from 52-week high
-7.39%
Change from 52-week low
112.27%
Change from all-time high
-32.3%
Change from all-time low
5,510.18%
Change from open
-2.14%
Day's gap
-0.15%
Dollar volume
$332.7M
High price
$69.68
Low price
$66.19
Monthly RSI
57.8
Open price
$68.61
Position in 52-week range
27.22%
Premarket change
-0.35%
Premarket close
$68.71
Premarket price
$68.47
Premarket volume
5.6K
Previous close
$68.71
Price vs 150-day SMA
11.53%
Price vs 20-day SMA
-1.03%
Price vs 200-day SMA
21.01%
Price vs 50-day SMA
1.17%
Relative volume
1.09
RSI
47.99
Sharpe ratio
1.64
Sharpe ratio (3Y)
0.12
Sharpe ratio (5Y)
0.11
Sortino ratio
2.63
Sortino ratio (3Y)
0.26
Sortino ratio (5Y)
0.27
Volume
5M
Weekly RSI
59.46
YTD price change
62.1%
YTD total return
62.1%
Ownership and float
Institutional, insider, float, short-interest, and share-count fields.
10
Metric
Value
Float
463.7M
Float percentage
93.66%
Shares change (QoQ)
-0.7%
Shares change (YoY)
0.16%
Shares held by insiders
0.35%
Shares held by institutions
93.82%
Shares outstanding
495.1M
Short % of float
2.27%
Short % of shares
2.12%
Short ratio
2.2 days
Deeper analysis on CNC
14 sections in the full report · jump straight to what you need
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
Frequently asked questions
About this CNC report
What is the latest published CNC stock rating?
Centene Corporation is shown with Reduce in the latest published report, analyzed 2026-10-04. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.
Where can I read the full CNC analysis?
The full latest published report, analyzed 2026-10-04, lives at /stocks/CNC/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.
What fair value is used for CNC?
The latest published report analyzed 2026-10-04 gives CNC a fair value of USD 51 and a potential value of USD 59. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.
How often is the CNC page updated?
The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-04). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
